Iannis Aifantis

Iannis Aifantis

Auto-generated profile, based on publicly available information

Iannis Aifantis

Department of Pathology, NYU Grossman School of Medicine, New York, USA

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2011 in Cancer Cell
Verified
Journal Article
Closed access
KMKelly Moran-Crusio
Kelly Moran-Crusio
LRLinsey Reavie
Linsey Reavie
ASAlan Shih
Alan Shih
OAOmar Abdel-Wahab
Omar Abdel-Wahab
DNDelphine Ndiaye-Lobry
Delphine Ndiaye-Lobry
RLRoss L. Levine
Ross L. Levine

10 April 2019 in Nature
Verified
Journal Article
Closed access
PDF file
ATAnastasia N. Tikhonova
Anastasia N. Tikhonova
IDIgor Dolgalev
Igor Dolgalev
HHHai Hu
Hai Hu
KSKishor K. Sivaraj
Kishor K. Sivaraj
EHEdlira Hoxha
Edlira Hoxha
IAIannis Aifantis
Iannis Aifantis

1 September 2017 in Cell
Verified
Journal Article
Closed access
LCLuisa Cimmino
Luisa Cimmino
IDIgor Dolgalev
Igor Dolgalev
YWYubao Wang
Yubao Wang
Akihide YoshimiAkihide Yoshimi
Akihide Yoshimi
GMGaëlle H. Martin
Gaëlle H. Martin
IAIannis Aifantis
Iannis Aifantis

6 February 2012 in Nature Medicine
Verified
Journal Article
Open access
PDF file
PNPanagiotis Ntziachristos
Panagiotis Ntziachristos
ATAristotelis Tsirigos
Aristotelis Tsirigos
PVPieter Van Vlierberghe
Pieter Van Vlierberghe
JNJelena Nedjic
Jelena Nedjic
TTThomas Trimarchi
Thomas Trimarchi
IAIannis Aifantis
Iannis Aifantis
T cell acute lymphoblastic leukemia (T-ALL) is an immature hematopoietic malignancy driven mainly by oncogenic activation of NOTCH1 signaling1. In this study we report the presence of loss-of-function mutations and deletions of the EZH2 and SUZ12 genes, which encode crucial components of the Polycomb repressive complex 2 (PRC2)2,3, in 25% of T-ALLs. To further study the role of PRC2 in T-ALL, we used NOTCH1-dependent mouse models of the disease, as well as human T-ALL samples, and combined locus-specific and global analysis of NOTCH1-driven epigenetic changes. These studies demonstrated that activation of NOTCH1 specifically induces loss of the repressive mark Lys27 trimethylation of histone 3 (H3K27me3)4 by antagonizing the activity of PRC2. These studies suggest a tumor suppressor role for PRC2 in human leukemia and suggest a hitherto unrecognized dynamic interplay between oncogenic NOTCH1 and PRC2 function for the regulation of gene expression and cell transformation.

1 July 2014 in Cell
Verified
Journal Article
Closed access
TTThomas Trimarchi
Thomas Trimarchi
EBErhan Bilal
Erhan Bilal
PNPanagiotis Ntziachristos
Panagiotis Ntziachristos
GFGiulia Fabbri
Giulia Fabbri
RDRiccardo Dalla-Favera
Riccardo Dalla-Favera
IAIannis Aifantis
Iannis Aifantis

17 August 2014 in Nature
Verified
Journal Article
Open access
PDF file
PNPanagiotis Ntziachristos
Panagiotis Ntziachristos
ATAristotelis Tsirigos
Aristotelis Tsirigos
GWG. Grant Welstead
G. Grant Welstead
TTThomas Trimarchi
Thomas Trimarchi
SBSofia Bakogianni
Sofia Bakogianni
IAIannis Aifantis
Iannis Aifantis
T-cell acute lymphoblastic leukaemia (T-ALL) is a haematological malignancy with a poor prognosis and no available targeted therapies; now two histone H3 lysine 27 demethylases, JMJD3 and UTX, are shown to have contrasting roles in human T-ALL cells and a mouse model of the disease, and a small molecule demethylase inhibitor is found to inhibit the growth of T-ALL cell lines, introducing a potential therapeutic avenue for acute leukaemia. Two histone H3 lysine 27 demethylases, JMJD3 and UTX, are shown here to have contrasting roles in human T-cell acute lymphoblastic leukaemia (T-ALL) cells and a mouse model of the disease. JMJD3 is overexpressed in T-ALL and essential for initiation and maintenance of disease, whereas UTX is a target of inactivating mutations in human T-ALL and acts a tumour suppressor. A small-molecule demethylase inhibitor inhibits the growth of T-ALL cell lines, introducing a potential therapeutic avenue for an acute leukemia that has a poor prognosis and no currently available targeted therapies. T-cell acute lymphoblastic leukaemia (T-ALL) is a haematological malignancy with a dismal overall prognosis, including a relapse rate of up to 25%, mainly because of the lack of non-cytotoxic targeted therapy options. Drugs that target the function of key epigenetic factors have been approved in the context of haematopoietic disorders1, and mutations that affect chromatin modulators in a variety of leukaemias have recently been identified2,3; however, ‘epigenetic’ drugs are not currently used for T-ALL treatment. Recently, we described that the polycomb repressive complex 2 (PRC2) has a tumour-suppressor role in T-ALL4. Here we delineated the role of the histone 3 lysine 27 (H3K27) demethylases JMJD3 and UTX in T-ALL. We show that JMJD3 is essential for the initiation and maintenance of T-ALL, as it controls important oncogenic gene targets by modulating H3K27 methylation. By contrast, we found that UTX functions as a tumour suppressor and is frequently genetically inactivated in T-ALL. Moreover, we demonstrated that the small molecule inhibitor GSKJ4 (ref. 5) affects T-ALL growth, by targeting JMJD3 activity. These findings show that two proteins with a similar enzymatic function can have opposing roles in the context of the same disease, paving the way for treating haematopoietic malignancies with a new category of epigenetic inhibitors.